cruzi insect stage is able to withstand 1 mM hemina concentration known to disrupt phospholipid membraneswithout any obvious toxic effect (Lara et al., 2009
Microglia-mediated Neuroinflammation: A potential target for the treatment of cardiovascular diseases
LY3298176, a novel long-acting GIP/GLP-1 coagonist, shows enhanced activity on weight loss and energy utilization whilst maintaining its efficacy for glycaemic control
Signae Vitae
Understanding that complete healing takes months helps set realistic expectations
GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S
:format(webp))
